JAK2 V617F and exon 12 genetic variations in Korean patients with BCR/ABL1-negative myeloproliferative neoplasms

Korean Journal of Laboratory Medicine

Volumn 30, Issue 6, 2010, Pages 567-574

  Kim, Jeong Tae ^a   Cho, Yong Gon ^a   Choi, Sam Im ^a   Young Jin, L ^b   Kim, Hye Ran ^c   Jang, Sook Jin ^d   Moon, Dae Soo ^d   Park, Young Jin ^d   Park, Geon ^d  

^a Chonbuk National University Medical School   (South Korea)

^b Wonkwang University   (South Korea)

^c Chonnam National University   (South Korea)

^d Chosun University College of Medicine   (South Korea)

Author keywords

Exon 12; JAK2; Myeloproliferative neoplasms; Rs56241661; V617F

Indexed keywords

BCR ABL PROTEIN; JANUS KINASE 2;

ADOLESCENT; ADULT; AGE; AGED; ALLELE; AMINO ACID SUBSTITUTION; ARTICLE; ASIAN; CHILD; DNA SEQUENCE; EXON; FEMALE; GENETIC VARIABILITY; GENETICS; HUMAN; MALE; METABOLISM; MIDDLE AGED; MYELOPROLIFERATIVE DISORDER; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK; SOUTH KOREA;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ALLELES; AMINO ACID SUBSTITUTION; ASIAN CONTINENTAL ANCESTRY GROUP; CHILD; EXONS; FEMALE; FUSION PROTEINS, BCR-ABL; GENETIC VARIATION; HUMANS; JANUS KINASE 2; MALE; MIDDLE AGED; MYELOPROLIFERATIVE DISORDERS; ODDS RATIO; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; REPUBLIC OF KOREA; SEQUENCE ANALYSIS, DNA;

EID: 78651298035     PISSN: 15986535     EISSN: None     Source Type: Journal    
DOI: 10.3343/kjlm.2010.30.6.567     Document Type: Article

References (33)

1. Tefferi A and Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 2008;22:14-22.
2. Kurzrock R, Kantarjian HM, Druker BJ, Talpaz M. Philadelphia chromosome-positive leukemias: from basic mechanisms to molecular therapeutics. Ann Intern Med 2003;138:819-30.
3. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005;352:1779-90.
4. Tefferi A and Gilliland DG. Oncogenes in myeloproliferative disorders. Cell Cycle 2007;6:550-66.
5. Delhommeau F, Jeziorowska D, Marzac C, Casadevall N. Molecular aspects of myeloproliferative neoplasms. Int J Hematol 2010;91: 165-73.
6. V617F mutation in Korean patients with essential thrombocythemia. Korean J Lab Med 2007;27:77-82.
7. Bang SM, Ahn JY, Park J, Yoo SJ, Park SH, Nam EM, et aL Diagnostic usefulness of the Janus kinase 2 mutation in non BCR/ABL myeloproliferative disorders. Korean J Intern Med 2006;21:219-24.
8. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005;365:1054-61.
9. Jones AV, Kreil S, Zoi K, Waghorn K, Curtis Q Zhang L et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 2005;106:2162-8.
10. Jones AV, Campbell PJ, Beer PA, Schnittger S, Vannucchi AM, Zoi K, et al. The JAK2 46/1 haplotype predisposes to MPL-mutated myeloproliferative neoplasms. Blood 2010;115:4517-23.
11. Michiels JJ and Juvonen E. Proposal for revised diagnostic criteria of essential thrombocythemia and polycythemia vera by the Thrombocythemia Vera Study Group. Semin Thromb Hemost 1997;23:33947.
12. Barosi G, Ambrosetti A, Finelli Q Grossi A, Leoni P, Liberato NL, et aL The Italian Consensus Conference on Diagnostic Criteria for Myelofibrosis with Myeloid Metaplasia. BrJ Haematol 1999,104:730-7.
13. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002; 100:2292-302.
14. Aplenc R, Orudjev E, Swoyer J, Manke B, Rebbeck T. Differential bone marrow aspirate DNA yields from commercial extraction kits. Leukemia 2002;16:1865-6.
15. Saltzman A. Stone M. Franks C. Searfoss G. Munro R. Jaye M. Ivashchenko Y. Cloning and characterization of human Jak-2 kinase: High mRNA expression in immune cells and muscle tissue Biochemical and Biophysical Research Communications 1998 246 3 627-633 DOI 10.1006/bbrc.1998.8685 15. Saltzman A, Stone M, Franks C, Searfoss G, Munro R, Jaye M, et al. doning and characterization of human Jak-2 kinase: high mRNA expression in immune cells and muscle tissue. Biochem Biophys Res Commun 1998;246:627-33. (Pubitemid 28420909)
16. Quentmeier H, MacLeod RA, Zaborski M, Drexler HG. JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders. Leukemia 2006;20:471-6.
17. Watanabe S. Arai K.-I. Roles of the JAK STAT system in signal transduction via cytokine receptors Current Opinion in Genetics and Development 1996 6 5 587-596 DOI 10.1016/S0959-437X(96)80088-8 17. Watanabe S and Arai K. Roles of the JAK-STAT system in signal transduction via cytokine receptors. Curr Opin Genet Dev 1996;6: 587-96. (Pubitemid 26372155)
18. Saharinen P. Takaluoma K. Silvennoinen O. Regulation of the Jak2 tyrosine kinase by its pseudokinase domain Molecular and Cellular Biology 2000 20 10 3387-3395 DOI 10.1128/MCB.20.10.3387-3395.2000 18. Saharinen P, Takaluoma K, Silvennoinen O. Regulation of the Jak2 tyrosine kinase by its pseudokinase domain. Mol Cell Biol 2000;20: 3387-95. (Pubitemid 30243884)
19. Percy MJ, Scott LM, Erber WN, Harrison CN, Reilly JT, Jones FG, et al. The frequency of JAK2 exon 12 mutations in idiopathic erythrocytosis patients with low serum erythropoietin levels. Haematologica 2007;92:1607-14.
20. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005;7:387-97.
21. Speletas M, Katodritou E, Daiou C, Mandala E, Papadakis E, Kioumi A, et al. Correlations of JAK2-V617F mutation with clinical and laboratory findings in patients with myeloproliferative disorders. Leuk Res 2007;31:1053-62.
22. Levine RL, Pardanani A, Tefferi A, Gilliland DG. Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat Rev Cancer 2007;7:673-83.
23. Bousquet M, Le Guellec S, Quelen C, Rigal-Huguet F, Delsol G, Brousset P. Frequent detection of the JAK2 V617F mutation in bone marrow core biopsy specimens from chronic myeloproliferative disorders using the TaqMan polymerase chain reaction single nucleotide polymorphism genotyping assay: a retrospective study with pathologic correlations. Hum Pathol 2006;37:1458-64.
24. Horn T, Kremer M, Dechow T, Pfeifer WM, Geist B, Perker M, et al. Detection of the activating JAK2 V617F mutation in paraffinembedded trephine bone marrow biopsies of patients with chronic myeoproliferative diseases. J MoI Diagn 2006;8:299-304.
25. Lay M, Mariappan R, Gotlib J, Dietz L, Sebastian S, Schrijver I, et al. Detection of the JAK2 V617F mutation by LightCycler PCR and probe dissociation analysis. J Mol Diagn 2006;8:330-4.
26. Barosi G, Bergamaschi G, Marchetti M, Vannucchi AM, GuglielmelIi P, Antonioli E, et al. JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis. Blood 2007;110:4030-6.
27. Tan AY, Westerman DA, Dobrovic A. A simple, rapid, and sensitive method for the detection of the JAK2 V617F mutation. Am J Clin Pathol 2007;127:977-81.
28. Pietra D, Li S, Brisci A, Passamonti F, Rumi E, Theocharides A, et al. Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders. Blood 2008;111:1686-9.
29. Schnittger S, Bacher U, Haferlach C, Geer T, Muller P, Mittermuller J, et al. Detection of JAK2 exon 12 mutations in 15 patients with JAK2 V617F negative polycythemia vera. Haematologica 2009;94:414-8.
30. Scott LM, Tong W, Levine RL, Scott MA, Beer PA, Stratton MR, et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 2007;356:459-68.
31. Butcher CM, Hahn U, To LB, Gecz J, Wilkins EJ, Scott HS, et al. Two novel JAK2 exon 12 mutations in J/LK2V617F-negative polycythaemia vera patients. Leukemia 2008;22:870-3.
32. NCBI Single Nucleotide Polymorphism, http://www.ncbi.nlm.nih.gov/ projects/SNP/snp-ref.cgi?rs=56241661 (Updated on Mar 2010).
33. Pardanani A, Lasho TL, Finke CM, Gangat N, Wolanskyj AP, Hanson CA, et al. The JAK2 46/1 haplotype confers susceptibility to essential thrombocythemia regardless of JAK2V617F mutational status-clinical correlates in a study of 226 consecutive patients. Leukemia 2010;24:1104.